Sign Up Today and Learn More About 4TEEN4 Pharmaceuticals Stock
Invest in or calculate the value of your shares in 4TEEN4 Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
4TEEN4 Pharmaceuticals Stock
4TEEN4 Pharmaceuticals GmbH develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
About 4TEEN4 Pharmaceuticals Stock
Founded
2013
Industries
Software, Artificial Intelligence, Data and Analytics
4TEEN4 Pharmaceuticals Press Mentions
Stay in the know about the latest news on 4TEEN4 Pharmaceuticals
4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases
globenewswire • Jul 15, 2025
4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases
morningstar • Jul 15, 2025
4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases
biospace • Jul 15, 2025
Methods for determining dpp3 and therapeutic methods
patents • May 04, 2025
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in …
patents • Feb 11, 2025
4TEEN4 Pharmaceuticals Management
Leadership team at 4TEEN4 Pharmaceuticals
Chief Executive Officer
Andreas Bergmann
CSO
Karine Bourgeois
Join now and verify your accreditation status to gain access to:
- 4TEEN4 Pharmaceuticals Current Valuation
- 4TEEN4 Pharmaceuticals Stock Price
- 4TEEN4 Pharmaceuticals Management
- Available deals in 4TEEN4 Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- 4TEEN4 Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- 4TEEN4 Pharmaceuticals Revenue and Financials
- 4TEEN4 Pharmaceuticals Highlights
- 4TEEN4 Pharmaceuticals Business Model
- 4TEEN4 Pharmaceuticals Risk Factors
- 4TEEN4 Pharmaceuticals Research Report from SACRA Research
Trading 4TEEN4 Pharmaceuticals Stock
How to invest in 4TEEN4 Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like 4TEEN4 Pharmaceuticals through EquityZen funds. These investments are made available by existing 4TEEN4 Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell 4TEEN4 Pharmaceuticals stock?
Shareholders can sell their 4TEEN4 Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."